与间歇性肺部疾病相关的肺高血压:最先进的技术审查
Ganesh Raghu1, Sandeep Sahay2, Laura C Price3
1University of Washington, Seattle, Washington, USA graghu@uw.edu.
The European respiratory journal
|March 12, 2026
概括
间歇性肺病 (ILD-PH) 中的肺高血压存在诊断和管理方面的挑战. 对生物标志物,成像和治疗的进一步研究对于改善患者的治疗结果至关重要.
科学领域:
- 肺部医学 肺部医学
- 心脏病学 心脏病学
背景情况:
- 肺高血压 (PH) 经常使间歇性肺部疾病 (ILD) 复杂化,显著恶化预后和生活质量.
- 在ILD (ILD-PH) 中诊断和管理PH是复杂的,因为ILD亚型异质,症状重叠.
- 目前的诊断方法依赖于侵袭性右心导管治疗 (RHC),突出了对少入侵方法的需求.
研究的目的:
- 提供对目前对ILD-PH.的理解的全面审查.
- 概述ILD-PH的临床特征,病理生理学,诊断,预后和治疗策略.
- 确定未来的研究方向,以改善ILD-PH管理.
主要方法:
- 本综述综合了关于ILD-PH的当前文献.
- 它检查了现有的诊断和治疗方式.
- 它突出了知识上的差距和未来研究的领域.
主要成果:
- ILD-PH的特点是由于ILD异质性和症状重叠导致的诊断挑战.
- 缺乏特定的生物标志物和依赖RHC使准确的评估变得复杂.
- 有前途的研究途径包括新型生物标志物,先进的成像和药理疗法评估.
结论:
- 多学科和个性化的护理策略对于管理ILD-PH至关重要.
- 需要进一步的研究来制定基于证据的指导方针,并改善患者的治疗结果.
- 对于ILD-PH患者来说,急需改善诊断和治疗干预措施.
更多相关视频
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
904
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
904
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
613
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
816
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
816
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
4.0K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
4.0K
Pulmonary Embolism I: Introduction
1.5K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.5K


